Schizophrenia Disease: Phases, Diagnosis and Outlook
Updated
Schizophrenia is a serious, usually long-term illness of the brain that changes how a person perceives reality, thinks and feels, and it is most often diagnosed between the ages of 16 and 30, often after a period of quieter changes. Like many long-term diseases, schizophrenia disease follows a course: a prodrome, a first episode of psychosis, an acute phase, a period of stabilisation and a longer stable or residual phase, sometimes with relapses along the way. The outlook is better than its reputation: in long-term studies of people treated for a first episode of psychosis, more than half reach remission. This guide follows the illness over time: how the diagnosis is made and which look-alike conditions are ruled out, the disorders on the schizophrenia spectrum, recovery and relapse figures, the physical health gap, what happens when treatment doesn't work, and the support that helps over the years. Every figure links to the guideline or study it comes from.
- Usual diagnosisBetween 16 and 30, after a first episode of psychosis (NIMH)
- Diagnosis needsSigns for at least 6 months, with at least 1 month of active symptoms (DSM-5-TR)
- Outlook58% remission and 38% recovery after a first episode (Lally 2017)
- Life expectancyAbout 14.5 years shorter on average, much of it from physical illness
- Crisis help in the USCall or text 988, the Suicide & Crisis Lifeline
What kind of disease is schizophrenia?
Schizophrenia is a serious mental illness that affects how a person thinks, feels and behaves, in the words of the US National Institute of Mental Health (NIMH), and research increasingly describes it as a disorder of brain structure, brain chemistry and brain networks. A 2022 Lancet seminar by Jauhar and colleagues summarises the established findings: enlarged lateral ventricles, brain volume reductions of around 2%, functional changes in parts of the frontal cortex, and disturbed dopamine and glutamate signalling. The genetic contribution is largely polygenic, meaning many genes each add a small amount of risk, and birth and early-life factors also play a part. The World Health Organization (WHO) estimates that schizophrenia affects about 1 in 300 people worldwide, around 27 million, and NIMH puts US estimates for schizophrenia and related psychotic disorders at 0.25% to 0.64%. The Lancet seminar adds that the disorder is modestly more common in men than in women, and that its outcome is not uniformly poor.
NIMH groups the symptoms into three kinds: psychotic symptoms such as hallucinations, delusions and disordered thinking; negative symptoms such as loss of motivation and withdrawal from social life; and cognitive symptoms, meaning problems with attention, concentration and memory. The age of onset differs by sex. NIMH says it usually begins in late adolescence to the early twenties in men, and in the early twenties to early thirties in women. Schizophrenia in young children is rare. Because the illness starts at an age when people are finishing education, starting work and forming relationships, how it is recognised and treated in the first years shapes much of what follows.
What are the phases of schizophrenia?
Schizophrenia usually unfolds in phases rather than starting overnight, and the Merck Manual describes premorbid, prodromal, early psychosis, middle and late phases of the illness. In the prodrome, subclinical symptoms appear: social withdrawal, irritability, suspiciousness, unusual thoughts, perceptual distortions and disorganisation, building over days or weeks in some people and over years in others. The first episode of psychosis follows, and NIMH says most people are diagnosed between the ages of 16 and 30, after that first episode. In the acute phase, hallucinations, delusions and disorganised thinking are active and, according to Merck, often at their worst; this is usually when treatment starts. Stabilisation follows as symptoms ease with treatment, and continuing that treatment protects against relapse. In the longer stable or residual phase, some people have few symptoms while others keep negative or cognitive symptoms. Merck notes that functioning may decline during the first five years after onset, after which disability tends to plateau.
Not everyone with prodrome-like changes goes on to develop psychosis. In a 2021 JAMA Psychiatry meta-analysis of 130 studies and 9,222 people at clinical high risk for psychosis, Salazar de Pablo and colleagues found a cumulative risk of transition to psychosis of 15% at one year and 25% at three years. Merck puts the figure at 20% to 40% even in an advanced prodrome. Most people at high risk therefore don't develop psychosis, but the risk is high enough for a specialist assessment to be worthwhile when a young person's thinking, mood or friendships change in ways that worry them or their family.
The later phases are less fixed than the old picture of steady decline. In a 2017 review of 79 first-episode studies, Lally and colleagues found that recovery rates stayed stable after the first two years and concluded that a progressively deteriorating course is not typical. The American Psychiatric Association (APA) patient guide adds that severe psychotic symptoms often lessen with age, while stopping medicine, substance use and stress tend to make symptoms worse.
How is schizophrenia diagnosed?
Schizophrenia is diagnosed clinically, by a psychiatrist or another trained clinician, using the criteria of the DSM-5-TR, the diagnostic manual of the American Psychiatric Association; no blood test or brain scan can confirm it, as the Merck Manual points out. In plain words, the criteria as Merck summarises them require at least two of five characteristic symptoms for at least one month: delusions, hallucinations, disorganised speech, disorganised behaviour and negative symptoms. At least one of the two must be delusions, hallucinations or disorganised speech. Work, relationships or self-care must have declined, and continuous signs of the illness must last at least six months, a period that can include quieter prodromal or residual stretches. Psychosis caused by a substance, a medicine or another medical condition has to be ruled out, and mood disorders with psychotic features and schizoaffective disorder have to be told apart. The APA patient guide stresses the same six-month rule and the need to rule out substance use and other medical or neurological causes.
Ruling out other causes is a real part of the workup, not a formality. The APA practice guideline suggests these assessments at the start:
- Substances: tobacco, cannabis, alcohol, stimulants and other drugs, and how they are used. Cannabis use may be linked to more severe symptoms or an earlier onset of psychosis, and other substances can produce or worsen psychotic symptoms.
- Thyroid and other blood tests: thyroid-stimulating hormone (TSH), electrolytes, kidney and liver function and a full blood count, with a pregnancy test when relevant and a drug toxicology screen if clinically indicated.
- The brain: brain imaging, with MRI preferred over CT, and an EEG when the neurological examination or history points that way.
- Mood disorders: bipolar disorder and major depression can both come with psychosis, which Merck lists among the conditions to tell apart.
A first diagnosis is not always the last one. The APA guideline notes that a significant fraction of people with psychosis have a change in diagnosis over time, so the diagnosis may need to be re-evaluated as the course becomes clearer, and specialist consultation helps when the symptoms or course look atypical or treatment isn't working. That leaves many questions in the first months: which tests have been done, what each one ruled out, and why the working diagnosis is schizophreniform disorder rather than schizophrenia. AskMed is a medical question app made for doctors, nurses, pharmacists, medical students and researchers. Instead of answering from memory, it searches journals, clinical guidelines and drug labels first, then writes an answer with a link after every claim. Ask it which assessments the APA guideline recommends before diagnosing schizophrenia after a first episode of psychosis, and it lists them with the guideline passage each one comes from, so you can read the wording yourself before the next appointment.
Ask AskMed what a first-episode psychosis workup includes:
Which conditions are on the schizophrenia spectrum?
The schizophrenia spectrum is the group of psychotic disorders that share features with schizophrenia but differ in how long the symptoms last, whether mood episodes are part of the picture and how far daily life is affected. The Merck Manual lists the related psychotic disorders as delusional disorder, brief psychotic disorder, schizophreniform disorder, schizoaffective disorder and schizotypal personality disorder, and notes that their diagnosis rests on symptoms and the course of the illness. The APA patient guide separates several of them by duration: brief psychotic disorder lasts between one day and one month, schizophreniform disorder lasts at least one month but less than six, and schizophrenia needs at least six months. Delusional disorder means false beliefs lasting at least one month without the other major symptoms. Schizoaffective disorder combines depressive or manic episodes with schizophrenia-like symptoms, and the guide says it is about one-third as common as schizophrenia. Psychosis caused by substances or another medical condition is ruled out before any of these.
- Brief psychotic disorder: psychotic symptoms lasting from one day to one month.
- Schizophreniform disorder: the symptoms of schizophrenia for at least one month but less than six; it is often the first working diagnosis while the course is still unclear.
- Schizophrenia: continuous signs for at least six months, including at least one month of active symptoms.
- Schizoaffective disorder: mood episodes alongside schizophrenia-like symptoms.
- Delusional disorder: fixed false beliefs for at least one month, without the other major symptoms of schizophrenia.
- Schizotypal personality disorder: listed by Merck among the related disorders.
What is the long-term outlook for schizophrenia?
The long-term outlook for schizophrenia varies widely from person to person, and the published figures depend heavily on how remission and recovery are defined. In the largest meta-analysis of first-episode psychosis, Lally and colleagues (British Journal of Psychiatry, 2017) pooled 79 studies of 19,072 people: 58% reached remission over an average follow-up of 5.5 years, and 38% met recovery criteria over an average of 7.2 years. Recovery rates held steady after the first two years, and remission rates have improved in more recent studies. Stricter definitions give lower numbers. Jääskeläinen and colleagues (Schizophrenia Bulletin, 2013) required lasting improvement in both symptoms and social functioning, and found a median of 13.5% across 50 studies, about 1 in 7. The WHO states that at least one in three people with schizophrenia will be able to fully recover, while some people have periods of worsening and remission throughout their lives. The Merck Manual gives 15% to 25% for recovery.
Some features point to a better course. The Merck Manual lists good functioning before the illness, a later or sudden onset, a family history of mood disorders, little cognitive impairment, few negative symptoms and a shorter duration of untreated psychosis, and says that the earlier and more intensive treatment starts, the better the outcome tends to be. The risks are real too: the APA guideline estimates that about 4% to 10% of people with schizophrenia die by suicide, with the highest rates among men early in the illness, which is one reason the first years after diagnosis deserve close support.
How can relapse be spotted and prevented?
Relapse, the return of acute psychotic symptoms after a period of improvement, is common in schizophrenia, and preventing it is one of the main aims of long-term care. In a study of 104 people who had responded to treatment for a first episode of schizophrenia or schizoaffective disorder, Robinson and colleagues (Archives of General Psychiatry, 1999) found a cumulative first-relapse rate of 81.9% within five years, and stopping antipsychotic medicine raised the risk of a first relapse almost five times. A Lancet meta-analysis by Leucht and colleagues (2012), covering 65 trials and 6,493 people, found that 27% of those who stayed on antipsychotic medicine relapsed within a year, compared with 64% of those switched to placebo. Early warning signs often come first: a 2024 review of 72 studies by Gleeson and colleagues found that changes in sleep, mood and suspiciousness predicted worsening symptoms, and Eisner and colleagues (2013) found that signs such as anxiety and insomnia tend to appear in the few weeks before a relapse.
- Sleep: sleeping much less than usual, or a disrupted sleep pattern.
- Mood and tension: new anxiety, irritability or low mood. A persistent low mood is worth raising on its own; a questionnaire such as the PHQ-9 can put a number on depressive symptoms to bring to an appointment.
- Suspiciousness: growing mistrust of other people or a feeling of being watched.
- Earlier symptoms returning: the voices, beliefs or confused thinking of a past episode starting again.
- Common triggers: stopping medicine, using cannabis or other drugs, and stress, which the APA patient guide says tend to worsen symptoms.
Warning signs are a reason to act, not a certainty: Eisner's review found a median sensitivity of 61% and specificity of 81% for predicting relapse. The APA guideline recommends that people whose symptoms have improved on an antipsychotic keep taking one, and suggests a long-acting injectable form for people who prefer it or whose adherence has been poor or uncertain. Family interventions help too: in the evidence review behind the guideline, relapse at 7 to 12 months was 30% with family intervention against 44% with usual care. In the UK, the NHS says a care plan may include an advance statement or crisis plan to be followed in an emergency, and advises never stopping an antipsychotic without speaking to the care team first.
Relapse prevention has many moving parts, and families and clinicians often want to see the evidence behind each one, from long-acting injectables to family work. AskMed can help here as well: ask it how family interventions compare with usual care for preventing relapse in schizophrenia, or what the evidence says about long-acting injectable antipsychotics after a first episode, and it answers with the trial and guideline figures, each linked to its source, so the plan you agree with your care team rests on studies you have read.
Look up the relapse-prevention evidence in AskMed:
- Get urgent help: if someone has thoughts of suicide or is in crisis, in the US call or text 988 or chat at 988lifeline.org, the 988 Suicide & Crisis Lifeline, as NIMH advises. If a life is in danger, call 911, or your local emergency number outside the US.
- Contact the care team the same day: if warning signs appear, if medicine has been stopped, or if symptoms are clearly returning. In the UK, the NHS says the care co-ordinator should give you and your family contact details for a crisis.
Why does physical health matter so much in schizophrenia?
Physical health matters in schizophrenia because much of the gap in life expectancy comes from physical illness rather than from the psychiatric condition itself. A Lancet Psychiatry meta-analysis by Hjorthøj and colleagues (2017), covering 11 studies and up to 247,603 patients, found an average of 14.5 years of potential life lost, with a weighted average life expectancy of 64.7 years: 59.9 years for men and 67.6 years for women. The gap had not narrowed over time. In a US Medicaid cohort of more than 1.1 million adults, Olfson and colleagues (JAMA Psychiatry, 2015) found that people with schizophrenia were 3.7 times as likely to die during follow-up as the general population; cardiovascular disease had the highest death rate, and deaths from chronic obstructive pulmonary disease were 9.9 times the expected number. The APA guideline links the excess to obesity, diabetes, high blood fats, heavier smoking, less health maintenance and unequal access to preventive care.
Smoking is the most modifiable part of that gap. A meta-analysis of 42 studies across 20 nations by de Leon and Diaz (2005) found a weighted odds ratio of 5.9 for current smoking in people with schizophrenia compared with the general population, and lower quit rates. The APA guideline recommends stopping smoking for anyone who smokes, using the same approaches as for the general population, and the NHS says a care plan should include support for giving up. Cardiometabolic risk starts early but grows: Mitchell and colleagues (2013) found metabolic syndrome in 9.9% of people with a first episode, and all metabolic risk factors were significantly less common early on than in people already established on antipsychotic medicine, so prevention works best from the start. The Merck Manual notes that the risk of metabolic syndrome is greater with second-generation antipsychotics.
Regular checks catch these problems. The APA guideline suggests measuring weight and body mass index at every visit for the first six months and at least every three months after that, with fasting glucose or HbA1c and a lipid panel four months after starting a new antipsychotic and at least once a year from then on, alongside pulse, blood pressure and checks for movement side effects. It is reasonable to ask whether these checks are being done, and whether a primary care clinician is involved as well as the mental health team.
What is treatment-resistant schizophrenia, and what helps long term?
Treatment-resistant schizophrenia means that significant symptoms persist despite adequate trials of antipsychotic medicine, and it affects a sizeable minority of people from the early stages of the illness. In a 2022 meta-analysis of 12 first-episode cohorts with 11,958 people, Siskind and colleagues (British Journal of Psychiatry) found treatment resistance in 22.8% of all first-episode cohorts and 24.4% of first-episode schizophrenia cohorts, and men were 1.57 times as likely as women to develop it. For clinical purposes, the APA guideline describes a common definition: no response, or only a partial response, to two different antipsychotic medicines, each tried for at least six weeks at an adequate dose, with adherence checked before a trial counts as failed. The APA recommends clozapine for treatment-resistant schizophrenia, and also when the risk of suicide stays substantial despite other treatment. NIMH notes that people taking clozapine need regular blood tests to watch for a potentially dangerous side effect.
Medicine is only one part of long-term care, and the APA guideline backs a broad set of services:
- Coordinated specialty care for a first episode: a team-based, recovery-focused programme with shared decision-making, family involvement, individual resilience training, supported work and education and individual medication treatment. The APA links it to lower relapse rates, better quality of life and a greater likelihood of working or studying after up to two years.
- Cognitive-behavioural therapy for psychosis (CBTp), psychoeducation and supported employment, all recommended by the APA.
- Assertive community treatment for people whose poor engagement with services has led to frequent relapse or social disruption such as homelessness.
- Family interventions, self-management and recovery-focused skills, cognitive remediation and social skills training, which the APA suggests.
- Treatment for substance use alongside schizophrenia care, which NIMH calls important for recovery.
Access is the weak point worldwide. The WHO says more than two out of three people with psychosis don't receive specialist mental health care, and it calls supported housing and supported employment essential, alongside a recovery-oriented approach that gives people a say in their own treatment and care in the community rather than in mental hospitals. For families, NIMH suggests helping the person get and stay in treatment, remembering that their beliefs or hallucinations seem very real to them, and looking into support groups and family education programmes.
Frequently asked questions
Is schizophrenia a lifelong disease?
It is usually long-term, but the course varies. After a first episode of psychosis, 58% reached remission and 38% met recovery criteria in a 2017 meta-analysis, and the WHO says at least one in three people with schizophrenia can fully recover. Others have periods of worsening and remission throughout life.
How long does the prodromal phase of schizophrenia last?
It varies from days or weeks to years, according to the Merck Manual. Not everyone in a prodrome-like state develops psychosis: in people at clinical high risk, the risk of transition was about 15% at one year and 25% at three years in a 2021 meta-analysis.
Can a brain scan or blood test diagnose schizophrenia?
No. Schizophrenia is diagnosed from symptoms and their course using DSM-5-TR criteria. Blood tests such as TSH, a drug screen when indicated and, if the history or examination suggests it, brain MRI or an EEG are used to rule out other causes of psychosis.
What is the difference between schizophrenia and schizoaffective disorder?
Schizoaffective disorder combines schizophrenia-like symptoms with depressive or manic mood episodes, while in schizophrenia mood episodes are not the main picture. The APA says schizoaffective disorder is about one-third as common as schizophrenia.
Why is life expectancy shorter with schizophrenia?
Mainly because of physical illness. A 2017 meta-analysis found 14.5 years of potential life lost on average, and heart disease, lung disease linked to smoking, diabetes and unequal access to care all contribute. Regular weight, glucose, lipid and blood pressure checks and help to stop smoking target that gap.
Can someone with schizophrenia stop medicine once they feel well?
Only together with the care team. In a first-episode study, stopping antipsychotic medicine raised the risk of relapse almost five times, and the APA recommends continuing an antipsychotic once symptoms have improved. Any change is best planned with the prescriber, with warning signs agreed in advance.
Sources
- National Institute of Mental Health. Schizophrenia (health topic) and Schizophrenia (publication). NIMH, US National Institutes of Health.
- National Institute of Mental Health. Schizophrenia statistics. NIMH.
- World Health Organization. Schizophrenia (fact sheet). WHO.
- American Psychiatric Association. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Third Edition. 2021. Executive summary: Keepers GA, Fochtmann LJ, Anzia JM, et al. Am J Psychiatry. 2020;177(9):868-872.
- American Psychiatric Association. What is schizophrenia? Reviewed March 2024.
- Keshavan MS. Schizophrenia and Introduction to schizophrenia and related disorders. Merck Manual Professional Edition. 2025.
- Jauhar S, Johnstone M, McKenna PJ. Schizophrenia. Lancet. 2022;399(10323):473-486.
- Salazar de Pablo G, Radua J, Pereira J, et al. Probability of transition to psychosis in individuals at clinical high risk: an updated meta-analysis. JAMA Psychiatry. 2021;78(9):970-978.
- Lally J, Ajnakina O, Stubbs B, et al. Remission and recovery from first-episode psychosis in adults: systematic review and meta-analysis of long-term outcome studies. Br J Psychiatry. 2017;211(6):350-358.
- Jääskeläinen E, Juola P, Hirvonen N, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. 2013;39(6):1296-1306.
- Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241-247.
- Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063-2071.
- Gleeson JF, McGuckian TB, Fernandez DK, et al. Systematic review of early warning signs of relapse and behavioural antecedents of symptom worsening in people living with schizophrenia spectrum disorders. Clin Psychol Rev. 2024;107:102357.
- Eisner E, Drake R, Barrowclough C. Assessing early signs of relapse in psychosis: review and future directions. Clin Psychol Rev. 2013;33(5):637-653.
- Hjorthøj C, Stürup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry. 2017;4(4):295-301.
- Olfson M, Gerhard T, Huang C, Crystal S, Stroup TS. Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry. 2015;72(12):1172-1181.
- de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005;76(2-3):135-157.
- Mitchell AJ, Vancampfort D, De Herdt A, Yu W, De Hert M. Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? A comparative meta-analysis of first episode, untreated and treated patients. Schizophr Bull. 2013;39(2):295-305.
- Siskind D, Orr S, Sinha S, et al. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. Br J Psychiatry. 2022;220(3):115-120.
- NHS. Schizophrenia: treatment. Reviewed April 2023.
